SCHEMBL2848586

SCHEMBL2848586

COC(=O)c1cc(Oc2ccc3nc(NCC4CCCCC4)sc3c2)nc(Cl)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.45
RAB9A P51151 6/20 0.45
MAPT P10636 3/20 0.45
ALDH1A1 P00352 2/20 0.44
PKM P14618 1/20 0.43
ITK Q08881 1/20 0.43
CSF1R P07333 4/20 0.42
PDGFRB P09619 1/20 0.42
KIT P10721 1/20 0.42
PDGFRA P16234 1/20 0.42
FLT3 P36888 1/20 0.42
CASP2 P42575 1/20 0.41
MAOB P27338 2/20 0.40
MAOA P21397 1/20 0.40
HSP90AA1 P07900 1/20 0.40
PIK3CA P42336 1/20 0.40
PI4KA P42356 1/20 0.40
PIK3CG P48736 1/20 0.40
PI4KB Q9UBF8 1/20 0.40
CSNK1D P48730 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2842436 0.83 CSF1R (0.49) NPC1RAB9AMAPTALDH1A1PKM
SCHEMBL2852610 0.83 NPC1 (0.47) NPC1RAB9AMAPTALDH1A1PKM
SCHEMBL2846605 0.82 CSF1R (0.47) NPC1RAB9AMAPTPKMCSF1R
SCHEMBL2845623 0.81 NPC1 (0.43) NPC1RAB9AMAPTALDH1A1PKM
SCHEMBL2845153 0.79 CSF1R (0.50) NPC1RAB9AMAPTPKMITK
SCHEMBL2845197 0.79 NPC1 (0.43) NPC1RAB9AMAPTPKMITK
SCHEMBL2840488 0.79 CSF1R (0.56) NPC1RAB9AMAPTPKMITK
SCHEMBL2841197 0.78 CSF1R (0.46) NPC1RAB9AMAPTPKMITK
SCHEMBL2677745 0.78 RAB9A (0.59) NPC1RAB9AMAPTALDH1A1ITK
SCHEMBL2676259 0.77 CSF1R (0.70) CSF1RPDGFRBKITPDGFRAFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2152700-B1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2013-12-11 EP disclosed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 US disclosed
EP-2152700-A1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE Novartis Ag (CH) 2010-02-17 EP disclosed
WO-2008144062-A1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2008-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE CSF1R, CSF3R, FLT3 NPC1 2714/4885RAB9A 1826/4885MAPT 3767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.